1 / 27

Ming T Tan, PhD University of Maryland Greenebaum Cancer Center Email: mtan@umm

Optimized Experimental Design for Detecting Synergy in Drug Combination Studies. Ming T Tan, PhD University of Maryland Greenebaum Cancer Center Email: mtan@umm.edu 2006 D.O.E. Presentation 7/11/2006. Combination Studies. Motivation: achieve greater efficacy with lesser toxicity

zanna
Download Presentation

Ming T Tan, PhD University of Maryland Greenebaum Cancer Center Email: mtan@umm

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Optimized Experimental Design for Detecting Synergy in Drug Combination Studies Ming T Tan, PhD University of Maryland Greenebaum Cancer Center Email: mtan@umm.edu 2006 D.O.E. Presentation 7/11/2006

  2. Combination Studies • Motivation: • achieve greater efficacy with lesser toxicity • provide a firmer basis for potential clinical trials • Joint action is divided into three types: 1.Independent joint action 2.Simple similar (additive) action 3.Synergistic/antagonistic action

  3. Current Design Methods • Equally regression lines (Finney, 1971) • An optimal design by fixing the total dose for specific models (Abdelbasit & Plackett, 1982) • Fixed ratio design (Tallarida et al., 1992) • An optimal design for in vitro combination studies (Greco et al., 1994) but the sample size too large • Uniform design based on the log-linear single dose-response (Tan et al., 2003)

  4. H0:f = 0 versus H1: f 0. Model Formulation The individual dose-response curves of drugs A and B are assumed: and The potency of B relative to A is For the additive action of A and B, the regression line for the mixture is The general nonparametric model for the combinations of A and B is assumed where the function is unspecified, Then, testing the additive action of A and B is equivalent to testing

  5. Model Assumptions With an invertible transformation: we have the additive structure and the model becomes where g1 and g2 are linearly independent, and satisfies the orthogonal condition:

  6. Model Formulation (cont’) Hence, testing the additive action of A and B is equivalent to testing H0:g = 0 versus H1: g 0 if g = 0, additive action in the mixture of A and B is implied; if g > 0, synergism in the mixture of A and B is implied; if g < 0, antagonism in the mixture of A and B is implied. The meaningful amount ( >0) of synergism or antagonism to be detected is specified by:

  7. Statistical Inference Suppose that are m mixtures of A and B in domain S ni experiments at the dose-level, yij are the corresponding responses, y:n  1 vector with elements yij ordered lexicographically, I: the unit matrix, 1k: the k1 vector of one, Z: m2 matrix with i-th row Under H0,

  8. Statistical Inference (cont’) Under H1: with where  is the design measure, which is a probability measure with mass pi = ni /n, i=1,2,…,m. If  is uniformly distributed on S, then and  is maximized, Uniform design measure maximizes the minimum power of the F-test for the additive action of drugs A and B.

  9. Uniform Scattered Points on C2 Fm(x)be the empirical distribution function ofPm, F(x)be the uniform distribution function in C2. Discrepancy: Let Um,2=(uij) be an m 2 matrix, each column is a permutation of {1,2,…,m}. Define vij=(uij - 0.5)/m, i=1,…,m; j=1,2, and Vm,2 can be considered as m points on C2. Then the uniform design is to choose the m points so that the discrepancy of Vm,2 is the smallest over all of possible Vm,2.

  10. Example: Uniform Scattered Points on C2 A uniform design with 7 experimental units on C2: Discrepancy: 0.1582 (smallest) The 7 experiment units: (0.071, 0.643), (0.214, 0.214), (0.357,0.929), (0.5, 0.5), (0.643, 0.071), (0.786, 0.786), (0.929, 0.357).

  11. Uniform Experimental Design Suppose the experimental domain (vi1, vi2)T, i=1,…,m; are m UD points on C2. The m Uniform design points on S are i=1,…,m Then, m mixtures {(xAi, xBi): i=1,…,m} of drugs A and B for experiment can be obtained by the inverse transform.

  12. Sample Size Determination • The sample sizes (number of experimental units) to detect a given meaningful synergism or antagonism can be calculated in term of the noncentral F-distribution. • When the alternative hypothesis H1 holds, the statistic Given: type I error rate (), power level (1- ), measurement variation (2), smallest meaningful difference (), the sample sizes can be obtained by

  13. Number of Replications 1 2 3 4 5 6 d = 0.2 -- 78 (234) 42 (168) 27 (135) 19 (114) 14 (98) d = 0.3 107 (214) 40 (120) 21 (84) 14 (70) 10 (60) 7 (49) d = 0.4 68 (136) 25 (75) 14 (56) 9 (45) 3 (18) 3 (21) d = 0.5 48 (96) 18 (54) 10 (40) 6 (30) 3 (18) 3 (21) d = 0.8 24 (48) 9 (27) 4 (16) 3 (15) 3 (18) 3 (21) Typical Designs: # of Experiments( = 0.05, 1-  =0.80)

  14. Layout of Experimental Design • Analyze single agent data and estimate single agent dose effects; • Choose the meaningful difference (2) and calculate the number of mixtures m; The variation (2) is estimated by the pooled variance from the two single agent experiments. • Define the domain S (e.g. ED20 to ED80) and find m mixtures of compounds A and B; • Upon completion of the experiment, use the F statistic to test the hypothesis of the additive action of A and B; • If p-value > 0.05, no detectable synergism; • Otherwise, we conclude the two compounds are synergistic or antagonistic. Using regression model selection methods to further diagnose the type of joint action of the two compounds

  15. Designs for Specific Dose-Effects(i) Linear dose-response curves The single dose-respose curves are E is the fractional effect The curves are produced in the low dose/low effect region for many agents: ionising radiation, enzyme inhibitors, mutagens, agents causing chromosomal abnormalities and environmental carcinogens. The potency of B relative to A: Model for the additive action: In combination experiment, the m mixtures should be uniformly scattered in the domain

  16. Designs for Specific Dose-Effects(ii) Linear-log dose-response curves The single dose-respose curves are The potency of B relative to A: Model for the additive action: In combination experiment, m combinations should be uniformly scattered in the domain Specially, when A=B, the total doses and the mixing proportions scatter uniformly on the domain. (Tan, et al. 2003)

  17. Designs for Specific Dose-Effects(iii) Sigmoid dose-response curves The single dose-respose curve or where Mis the median effective dose or concentration and m is a constant giving the order of sigmoidicity of the curve. The curves have been used in enzymology, also in studies of drugs causing muscle contraction, neuronal activators,inhibitors of cell proliferation and tumor promoters, and in general toxicology. The experimental design is the same as in the case (ii).

  18. Designs for Specific Dose-Effects(iv) Simple exponential dose-response curves, survivor multiplication The single dose-response curve S is the survival rate. Exponential dose-response curves are typically found in cell survival experiments with ionising and non-ionising radiation and other agents with dammage DNA, particularly alkylating agents. Since the experimental design is same as in the case (i).

  19. Example: SAHA+VP-16 Goal: to determine the effect of SAHA combined with VP-16 against the cell line HL-60 SAHA: 60 observations, dose range from 0.03 M to 10 M mean viability: 67.57%, standard deviation: 37.47 the dose-response curve VP-16: 60 observations, dose range from 0.003 M to 3 M mean viability: 64.05%, standard deviation: 27.88 The potency of VP-16 relative to SAHA is 9.12.

  20. SAHA+VP-16: Experimental Design The pooled variance: 836.176 the meaningful difference: 15% viability type I error rate: 0.05, power: 80%. Sample size: 90 (18 mixtures with 5 replications) The U-type matrix with 18 experiments (discrepancy: 0.0779) Dose range: 0.019M to 2.974M according to VP-16 (the viability is from 25% to 85%)

  21. SAHA+VP-16: Mixtures for combination experiment

  22. SAHA+VP-16:Results of Combination Experiment Dose ranges: SAHA: 0.405~18.708M, VP-16: 0.031~2.35M 90 observations: viability: 16.27%~113.06% mean:29.27% standard error: 15.92 F-test: F(3, 85)=60.63 p-value<0.0001 We reject H0: SAHA with VP-16 against HL-60 has the additive action

  23. SAHA+VP-16: Synergy Analysis The response regression model of combination study (1) The expected response model for the additive action of SAHA and VP-16 should be (2) Compare the equations (1) and (2): ·   If (1)-(2) = 0, SAHA and VP-16 is additive; ·   If (1)-(2) < 0, SAHA and VP-16 is synergistic; ·   If (1)-(2) > 0, SAHA and VP-16 is antagonistic.

  24. SAHA+VP-16: Contour Plot

  25. Conclusions • Based on the single dose-effect curves, we proposed an optimal design for testing the additive joint action of two compounds in vitro or in vivo. • under a general dose-response model, the maximum information is extracted by having the experimental points scattered uniformly on the two-dimensional experimental domain. • The design is optimal:Minimizing the variability in modeling synergism and extracting maximum information on the joint action of two compounds. • The number of experimental units (or runs) are quite feasiblein vitro or in vivo.

  26. Ming Tan, PhD Guoliang Tian, PhD Peter Houghton, PhD Douglas Ross, M.D., PhD Ken Shiozawa, PhD. Acknowledgements

More Related